Enhanced Multiplex IHC Technology for Precision Oncology

Life Sciences, Clinical Trials, Drug Discovery & Development, Biomarkers, Laboratory Technology,
  • Thursday, February 22, 2024

Unlock the potential of cutting-edge technology in oncology research. Dive into the latest breakthroughs in multiplex immunohistochemistry (IHC) during this upcoming webinar about Veracyte’s Brightplex® technology, a prominent example of multiplex IHC advancements. This webinar will explore innovative features that elevate the capabilities of this technology, providing a deeper understanding of not only the tumor microenvironment (TME) but also the critical imperative for biomarkers in the context of clinical trials.

Brightplex’s new features incorporate in situ hybridization (ISH) probes for the detection of RNA transcripts alongside traditional multiplex IHC biomarkers. This innovative approach allows the simultaneous detection of several protein expressions and RNA transcripts, facilitating a more complete understanding of the complex molecular dynamics within the TME. The technology is particularly relevant when no or poor antibodies are available for a specific target. Complex cell phenotypes can still be analyzed by combining RNA transcripts and proteins. The featured speakers will showcase how this multimodal technology can significantly enhance biomarker studies.


Adding another layer to this advancement is a new spatial analysis tool, offering the ability to analyze the distances between multiple cell populations of interest on sequential slides. This feature enables researchers and clinicians to explore the spatial relationships within the tumor, providing crucial information for a deeper understanding of the TME.

This webinar is in line with the ever-growing need for biomarkers in clinical trials. Biomarkers serve as indispensable tools for patient stratification, treatment response monitoring and overall trial success. The integration of advanced multiplex IHC technology not only expedites the identification of relevant biomarkers but also provides a more comprehensive understanding of their spatial context within the TME.

This technology goes beyond conventional approaches, empowering researchers to decipher intricate cellular interactions and identify biomarkers with unprecedented precision. The webinar will showcase real-world case studies, illustrating how these advancements have already made an impact in oncology research.

Read Less...

Join this webinar where experts will walk attendees through the strengths of Veracyte’s Brightplex technology and how their team can help your organization uncover insights on the underlying mechanisms of therapy response and resistance at the individual and cohort level.


Jacques Fieschi, Veracyte

Jacques Fieschi, PhD, VP of Research & Development, Veracyte

Jacques Fieschi is the Vice President of Research & Development (R&D) at Veracyte. In this role, he leverages his extensive experience in the biotechnology industry to push the boundaries of scientific discovery in immuno-oncology. Previously, he was a key member of the R&D team at HalioDx, an immuno-oncology diagnostics company acquired by Veracyte in August 2021. Earlier in his career, Dr. Fieschi held pivotal positions in R&D at Beckman Coulter, a life sciences manufacturing company, and QIAGEN, a biotechnology research company, where he played a crucial role in advancing cutting-edge technologies. Dr. Fieschi holds a PhD from CNRS (Centre National de la Recherche Scientifique) in France. In addition, he completed post-doctoral work as a research fellow at the French Alternative Energies and Atomic Energy Commission, or CEA, a French public government-funded research organization.

Message Presenter
Aurélie Auguste, Veracyte

Aurélie Auguste, PhD, Director, Translational Data Analysis, Veracyte

Aurélie Auguste is Director of Translational Data Analysis at Veracyte. In this role, she oversees a team of experts in bioinformatics and immuno-oncology, and she is at the forefront of cutting-edge research. Prior to this, Dr. Auguste served as a Senior Biomarker Expert at Boehringer Ingelheim, where she led translational studies in oncology and managed the Molecular Histopathology platform. Her earlier contributions include impactful work at Gustave Roussy in translational research in gynecological cancer, following her completion of a PhD at the French National Research Institute for Agriculture, Food and the Environment.

Message Presenter

Who Should Attend?

Biopharma teams involved in immuno-oncology with responsibilities including, but not limited to:

  • Biomarker discovery
  • Translational medicine
  • Clinical development
  • CDx development

What You Will Learn

  • Learn the latest advancements surrounding Veracyte’s multiplex IHC assay
  • Discover how coupling IHC and ISH can help in cancer research and drug development
  • Explore how spatial biology and image analysis can help provide actionable and efficient insights into the tumor microenvironment (TME)

Xtalks Partner


Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte engages in strategic collaborations with biopharmaceutical researchers to provide comprehensive support for their cancer drug development initiatives. In doing so, we offer a wide range of tools and services to support translational research, clinical development, commercial access, and companion diagnostics.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account